Abstract
Context: Circulating microRNA (miRNA) is of great importance to thebiomarker basednon-invasive cancer diagnosis. Objective: To identify circulating biomarkers for cancer screening and its usability with a micro fluidic device for developing an easy to use, cost effective screening tool by way of a blood test. Method: Reviewed published literature for expression of onco-miRNAs and miR-21(microRNA-21) in cancer patients’ serum and their detection methods. Results: miR-21 was chosen as circulating biomarker for breast cancer screening and testeda microfluidic device for breast cancer with 21 breast cancer and 30 healthy volunteers’ blood samples, results concurred with qPCR, the gold standard for quantification. Conclusion: In comparison to mammogram, which is the gold standard for breast cancer screening, microfluidic platform-based blood test for screening can reach a large population at affordable cost.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Public Health Review: International Journal of Public Health Research
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
